These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 16775978)

  • 41. HIV drug resistance threshold survey using specimens from voluntary counselling and testing sites in Hanoi, Vietnam.
    Nguyen HT; Duc NB; Shrivastava R; Tran TH; Nguyen TA; Thang PH; McNicholl JM; Leelawiwat W; Chonwattana W; Sidibe K; Fujita M; Luu CM; Kakkar R; Bennett DE; Kaplan J; Cosimi L; Wolfe MI
    Antivir Ther; 2008; 13 Suppl 2():115-21. PubMed ID: 18575200
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Drug resistance among chronic HIV-1-infected patients naïve for use of anti-retroviral therapy in Sao Paulo city.
    Gonsalez CR; Alcalde R; Nishiya A; Barreto CC; Silva FE; de Almeida A; Mendonça M; Ferreira F; Fernandes SS; Casseb J; Duarte AJ
    Virus Res; 2007 Nov; 129(2):87-90. PubMed ID: 17686543
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Selection of drug-resistant HIV-1 during the early phase of viral decay is uncommon in treatment-naïve patients initiated on a three- or four-drug antiretroviral regimen including lamivudine.
    Bergroth T; Ekici H; Gisslén M; Loes SK; Goh LE; Freedman A; Lampe F; Johnson MA; Sönnerborg A
    J Med Virol; 2009 Jan; 81(1):1-8. PubMed ID: 19031460
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Relationship between mutations in HIV-1 RNase H domain and nucleoside reverse transcriptase inhibitors resistance mutations in naïve and pre-treated HIV infected patients.
    Roquebert B; Wirden M; Simon A; Deval J; Katlama C; Calvez V; Marcelin AG
    J Med Virol; 2007 Mar; 79(3):207-11. PubMed ID: 17245724
    [TBL] [Abstract][Full Text] [Related]  

  • 46. HIV-1 reverse transcriptase inhibitor resistance mutations and fitness: a view from the clinic and ex vivo.
    Martinez-Picado J; Martínez MA
    Virus Res; 2008 Jun; 134(1-2):104-23. PubMed ID: 18289713
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Incorporating drug-resistance measurements into the clinical management of HIV-1 infection.
    Zolopa AR
    J Infect Dis; 2006 Sep; 194 Suppl 1():S59-64. PubMed ID: 16921474
    [TBL] [Abstract][Full Text] [Related]  

  • 48. New drug targets for HIV.
    Bean P
    Clin Infect Dis; 2005 Jul; 41 Suppl 1():S96-100. PubMed ID: 16265623
    [TBL] [Abstract][Full Text] [Related]  

  • 49. HIV drug resistance testing.
    Cane P
    Methods Mol Biol; 2011; 665():123-32. PubMed ID: 21116799
    [TBL] [Abstract][Full Text] [Related]  

  • 50. What's next? Treatment options when the first antiretroviral regimen fails virologically or is not tolerated, Part 1.
    Ruane PJ; Daar ES
    AIDS Read; 2004 Aug; 14(8):421-6, 431-2, 434. PubMed ID: 15338522
    [TBL] [Abstract][Full Text] [Related]  

  • 51. HIV drug resistance.
    Calmy A; Pascual F; Ford N
    N Engl J Med; 2004 Jun; 350(26):2720-1. PubMed ID: 15215494
    [No Abstract]   [Full Text] [Related]  

  • 52. Drug-drug interactions involving new antiretroviral drugs and drug classes.
    Soodalter J; Sousa M; Boffito M
    Curr Opin Infect Dis; 2009 Feb; 22(1):18-27. PubMed ID: 19532077
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Is HIV more and more resistant?].
    Chaix ML; Delaugerre C; Viard JP
    Rev Prat; 2004 Mar; 54(5):471-4. PubMed ID: 15176501
    [No Abstract]   [Full Text] [Related]  

  • 54. Resistance to antiviral drugs is climbing.
    Kmietowicz Z
    BMJ; 2005 Aug; 331(7512):308. PubMed ID: 16081434
    [No Abstract]   [Full Text] [Related]  

  • 55. [Clinical indications for resistance testing HIV infection].
    Maroto Vela Mdel C
    An R Acad Nac Med (Madr); 2010; 127(4):749-58; discussion 758-62. PubMed ID: 22263357
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Promising phase I results against new HIV target.
    Whelan J
    Drug Discov Today; 2004 Oct; 9(19):823. PubMed ID: 15381130
    [No Abstract]   [Full Text] [Related]  

  • 57. Resistance testing in drug-naive HIV-infected patients: is it time?
    Hecht FM; Grant RM
    Clin Infect Dis; 2005 Nov; 41(9):1324-5. PubMed ID: 16206109
    [No Abstract]   [Full Text] [Related]  

  • 58. HIV and contraception.
    Qureshi SK
    J Fam Plann Reprod Health Care; 2006 Apr; 32(2):134; author reply 134. PubMed ID: 16824323
    [No Abstract]   [Full Text] [Related]  

  • 59. Combating antiretroviral resistance.
    Jordan W
    J Natl Med Assoc; 2004 Feb; 96(2 Suppl):31S-32S. PubMed ID: 14977297
    [No Abstract]   [Full Text] [Related]  

  • 60. Access to antiretrovirals still too scarce in many countries.
    Zarocostas J
    BMJ; 2006 Apr; 332(7544):748. PubMed ID: 16575051
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.